VGX Inter, scale 284 million hepatitis B DNA vaccine supply contract
ADMIN ADMIN 2013.10.18 13:57 10/18/2013 13:57
VGX Inter (KOSPI: 011000) today, "Inovio scale and 284 million hepatitis B DNA vaccine supply contract was signed," he said. . Click geumbeon contract amount is approximately 30 billion multinational pharmaceutical company Roche to start the DNA vaccine drug development means that the two began in earnest.
Last month, the world of Inovio pharma Roche and hepatitis B DNA vaccine for prostate cancer research in collaboration to develop a DNA vaccine that has entered into a licensing agreement. VGX This license agreement is due to the inter-VGX licensing royalty income generated by the direct beneficiaries other than the United States benefit from increased sales of overseas subsidiaries in Houston will also suffer.
VGX DNA Inter CEO VGX bakyounggeun "Inovio Roche signed a contract with one of the first DNA vaccine for hepatitis B, as requested production of DNA vaccines business opportunities by Roche's non-clinical studies and clinical trials are expected to take place quickly much larger because of the DNA vaccine in future supply contracts are expected to be made constantly, "he said.
VGX DNA (FDA) (EMEA) VGX inter-plasmid DNA vaccine production facility in the United States, the Food and Drug Administration (FDA) and the European and Drug Administration (EMEA) meet the guidelines of this world, and the plasmid-based biopharmaceutical research and development organizations, universities, government and non-biotech companies clinical and clinical trials, and has supplied plasmid DNA
It was not reported because Dr. Kim stopped caring about wallstreet. He got his first of many contracts for 2 vaccines. He is now producing the product (the DNA plasmids encoding the hepatitis B proteins for vaccination purposes.
Why did Roche buy the hep B vaccine? According to the World Health Organtization here were over 59million health care workers worldwide in their census in 2005. Most are working in unsafe health conditions, but every one of them should be vaccinated with the Hep B vaccine. The current Hep B vaccine vaccinates against one protein of Hep B (the surface antigen), and that should be enough for protective immunity. However, the vaccine is #$%$ poor, and everyone knows it.
It works very poorly in men for some reason. When I was in medical school, I had to prove a positive titer for the vaccine to go on away rotations to other medical schools. Well my original vaccine in high school (a set of 3 vaccines), yielded an undetectable titre of protective antibody. So I had to get another round of 3 more hep B vaccines.
Well guess what. They checked my titre again after this set of 3, and my titre was still undetectable. I got another set of 3 vaccines 1 month later, and finally I showed a demonstrable (protective) titre of Hep B surface antigen antibodies, but just barely.
My brother also required 2 rounds (not 3) of the vaccine to get protective immunity.
I bet you if you check my titre, it will be back down to zero.
Roche knows this. INO knows this.
Even if 1/4 of the 59 million health care workers in the world get this vaccine, that's still a large number of people. And there is more people going into the health care profession everyday. Also there will be some high risk patients that want to get the vaccine as well.
15 million x $40= $600 million right now, for a truly protective vaccine. Not too shabby.
I went through 2 rounds hep vaccine and never developed a titer from either. Now I have to sign paper that I have tried twice and do not respond to the vaccine. The market is so wide open for INO it just crazy someday they will just be printing money with these plasmids and EP.